title: Alitretinoin: in severe chronic hand eczema.
abstract: Alitretinoin is an endogenous retinoid and acts as a pan-agonist at retinoid receptors, binding with high affinity to both retinoic acid receptors and retinoid X receptors (RXR). Oral alitretinoin once daily is approved for use in patients with severe chronic hand eczema unresponsive to treatment with potent topical corticosteroids. In a large (n = 1032), randomized, double-blind, placebo-controlled, multicentre study (BACH) of up to 24 weeks' duration in adults with severe chronic hand eczema, significantly more patients in the alitretinoin 10 or 30 mg/day groups than in the placebo group responded to treatment with clear/almost clear hands, as assessed by the Physician Global Assessment (PGA) [primary endpoint]. In an extension phase of the BACH study, alitretinoin was effective in patients who relapsed after responding to initial treatment with the drug. Of patients who had responded to initial treatment with alitretinoin 30 mg/day, significantly more alitretinoin 30 mg/day than placebo recipients responded on the PGA with clear/almost clear hands during the extension phase (primary endpoint; 80% vs 8%). Of those who had responded to initial treatment with alitretinoin 10 mg/day, 48% of alitretinoin 10 mg/day and 10% of placebo recipients responded during the extension phase. Alitretinoin was generally well tolerated in clinical trials excluding pregnant women. The most common treatment-emergent adverse events and abnormal laboratory test results were consistent with those previously observed with other oral retinoids and RXR agonists.
authors.affiliation: Wolters Kluwer Health/Adis, 41 Centorian Drive, Mairangi Bay, North Shore 0754, Auckland, New Zealand. demail@adis.co.nz
authors.forename: Karly P
authors.initials: KP
authors.lastname: Garnock-Jones
authors.forename: Caroline M
authors.initials: CM
authors.lastname: Perry
mesh_terms: D000328:Adult; D000077556:Alitretinoin; D002648:Child; D002908:Chronic Disease; D004485:Eczema / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006225:Hand / Q000473:pathology; D006801:Humans; D011247:Pregnancy; D016032:Randomized Controlled Trials as Topic; D047488:Retinoid X Receptors / Q000819:agonists; D012867:Skin / Q000473:pathology; D014212:Tretinoin / Q000008:administration & dosage / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology / Q000627:therapeutic use*
chemical_list: D047488:Retinoid X Receptors; D000077556:Alitretinoin; D014212:Tretinoin
references.citation: J Am Acad Dermatol. 1996 Mar;34(3):513-5
references.pmid: 8609271
references.citation: Cell. 1992 Jan 24;68(2):397-406
references.pmid: 1310260
references.citation: J Invest Dermatol. 2007 Jul;127(7):1568-70
references.pmid: 17568797
references.citation: Am J Clin Dermatol. 2000 Sep-Oct;1(5):307-14; discussion 315-6
references.pmid: 11702321
references.citation: Exp Dermatol. 2006 Jun;15(6):406-20
references.pmid: 16689857
references.citation: J Neuroimmunol. 2006 Feb;171(1-2):135-44
references.pmid: 16303184
references.citation: Dermatol Ther. 2004;17(3):240-50
references.pmid: 15186370
references.citation: Arch Dermatol. 2004 Dec;140(12):1453-9
references.pmid: 15611422
references.citation: Nature. 1992 Aug 13;358(6387):587-91
references.pmid: 1323763
references.citation: Contact Dermatitis. 2008 Jul;59(1):43-7
references.pmid: 18537992
references.citation: Br J Dermatol. 2008 Apr;158(4):808-17
references.pmid: 18294310
references.citation: Dermatology. 1999;199(4):308-12
references.pmid: 10640839
references.citation: Pharmacol Rev. 2006 Dec;58(4):712-25
references.pmid: 17132850
references.citation: Pharmacol Rev. 2006 Dec;58(4):760-72
references.pmid: 17132853
references.citation: Genes Dev. 1995 May 1;9(9):1033-45
references.pmid: 7744246
references.citation: Breast Cancer Res Treat. 1996;38(1):85-96
references.pmid: 8825126
references.citation: Contact Dermatitis. 2007 Oct;57(4):203-10
references.pmid: 17868211